When one company failed, it joined the other to accelerate the development and manufacture of a successful vaccine. Governments, retail pharmacies, health systems, payers, and nonprofits are working together to provide widespread distribution and administration.

Amid the tragic consequences of COVID-19, life sciences and medtech companies emerged as lights in the darkness. Decades of scientific work and investment seemed to be overnight successes. The heroic dedication of health care providers was met by the fastest novel vaccine development in history. Traditional competitors partnered to accelerate research and manufacturing.

Amid the tragic consequences of COVID-19, life sciences and medtech companies emerged as lights in the darkness. Decades of scientific work and investment seemed to be overnight successes. The heroic dedication of health care providers was met by the fastest novel vaccine development in history. Traditional competitors partnered to accelerate research and manufacturing. When one company failed, it joined the other to accelerate the development and manufacture of a successful vaccine. Governments, retail pharmacies, health systems, payers, and nonprofits are working together to provide widespread distribution and administration.

The landscape of hematological malignancies emerging therapeutics is massively growing, with many emerging and legacy companies venturing into the industry with their respective therapeutic portfolio exclusively developed and designed for the targeted treatment of hematological malignancies such as leukemia, lymphoma, and multiple myeloma. In the era of precision medicine, the introduction of monoclonal antibody- and CAR-T cell-based therapies have garnered a new hope in the oncology community, owing to their ability to induce effective response for the treatment of hematological malignancies. Hematological malignancies are very complex to treat due to their varying pathological and immunological characteristics,

Earth observation data and services market cater to different end-users such as government and defense, archaeology and civil infrastructure, energy and natural resources, agriculture, forestry and fishery, and maritime. In 2020, the global satellite Earth observation market was dominated by government and defense, energy, and natural resources. This is due to the high utilization of data and services in addressing military and tactical surveillance, monitoring of critical structures and ground assets, mining exploration, soil erosion monitoring, oil exploration, and optimization of renewable energy production.

With the increase in awareness regarding the harmful effects posed by synthetic chemicals, consumers are now abstaining from using chemical-infused products. In many instances, it has been found that toxic chemicals are being used in low-quality products, hence causing life-threatening problems in some cases. This led to an increase in awareness among consumers across the globe, resulting in an increase in the demand for natural products. The organic and bio-based beauty boom is part of the recent shift in consumer awareness about wellness, health, and the environment. Moreover, due to a growing number of social media influencers and beauty blogs, awareness, and availability of information regarding toxin-free ingredients have significantly risen.

Next-generation sequencing (NGS) is a disruptive technological development in the life sciences industry, which has paved the path for the development of several breakthrough medical procedures that are aimed to address the primary concern for global health. The development of next-generation sequencing technology has introduced fundamental changes in the process of genome sequencing in order to reduce cost and turnaround time. With its immense potential, NGS enables the understanding of the threat that a particular disease can pose to an individual and aid in the development of precise curative medical procedures. The current study aims to assess the global NGS sample preparation market by focusing on products (consumables, standalone automation instruments, automated workstation, accessories, and components) catering to end users, including hospitals and clinics, academic and research institutions, pharmaceutical and biotechnology companies, other end users (non-profit organizations, reference laboratories, and others). The current market for NGS sample preparation is majorly dominated by manufacturers and service providers such as Aurora Biomed, Inc., Bio-Rad Laboratories, Danaher Corporation, BGI, Eppendorf AG, F. Hoffmann-La Roche Ltd., Hamilton Company, Illumina, Inc., New England Biolabs, Inc., Oxford Nanopore Technologies, Ltd., QIAGEN, PerkinElmer, Inc., and Promega Corporation.